What 4 Analyst Ratings Have To Say About Regenxbio
Portfolio Pulse from Benzinga Insights
Over the past three months, four analysts have published their opinions on Regenxbio (NASDAQ:RGNX) stock. The average price target is $34.25, compared to the current price of $16.86, implying an upside. However, this average represents a 20.35% decrease from the previous average price target of $43.00.
October 04, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Analysts have given a mixed review of Regenxbio's stock, with an average price target of $34.25, which is higher than the current price but lower than the previous target.
The mixed reviews from analysts indicate uncertainty about the stock's future performance. The average price target suggests potential for growth, but the decrease from the previous target may indicate less optimism about the stock's potential.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100